The creation of commercial cord blood banks rests on the promise of stem cell based regenerative medicine and marks the capitalization of human tissues within a future-oriented “regime of hope”. This paper will present data from a survey of the international cord blood banking industry and will explore: (a) the way firms seek to commercialize cord blood as a new set of commodities; (b) the expectations and moral economy that are being constructed around this technology; and (c) how firms are acting as mediators of hope in what might be called a “promissory bioeconomy”.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: